Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired SelectQuote, Inc. securities between September 9, 2020, and May 1, 2025, due to allegations of misconduct related to Medicare Advantage plans [1][2]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company the most, regardless of the quality of those plans [2]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans and received illegal kickbacks from insurers [2][3]. - The U.S. Department of Justice filed a complaint against SelectQuote, stating that the company received "tens of millions of dollars" in illegal kickbacks from 2016 to at least 2021 [3]. Group 2: Impact on Stock and Legal Proceedings - Following the DOJ's allegations, SelectQuote's stock price dropped by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025 [3]. - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by October 10, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for failing to disclose an investigation by the U.S. Department of Justice regarding potential violations of the False Claims Act [1][2]. Allegations - The lawsuit alleges that Semler Scientific did not disclose a material investigation by the DOJ into possible violations of the False Claims Act during the class period from March 10, 2021, to April 15, 2025 [2]. - On February 28, 2025, Semler Scientific revealed it had received an initial civil investigative demand from the DOJ in July 2017, investigating whether the company violated the False Claims Act by marketing certain tests as reimbursable by Medicare [3]. - Following unsuccessful settlement discussions with the DOJ on February 11, 2025, the company faced a risk of a civil lawsuit, leading to a stock price drop of $4.03, or 9.38%, closing at $38.89 on March 3, 2025 [3]. Settlement and Financial Impact - On April 15, 2025, Semler Scientific reported to the SEC that it had reached a settlement agreement with the DOJ for $29.75 million, excluding attorney fees, but noted that further payments might be necessary and the risk of a DOJ lawsuit still exists [4]. - Following the settlement announcement, Semler Scientific's stock price fell by $3.40 per share, or 9.88%, closing at $31.00 on April 16, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against SelectQuote, Inc. for allegedly violating the False Claims Act by directing Medicare beneficiaries to insurers that compensated the company the most, rather than providing unbiased comparisons of insurance plans [1][2][3]. Group 1: Allegations and Legal Issues - The complaint alleges that SelectQuote failed to disclose that it directed Medicare beneficiaries to plans based on compensation rather than quality [2]. - SelectQuote is accused of not providing unbiased comparisons for Medicare Advantage plans and receiving illegal kickbacks from insurers [2]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to 2021, leading to a significant drop in its stock price by 19.2% on May 1, 2025 [3]. Group 2: Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by October 10, 2025 [4]. - Shareholders can remain absent class members and still be eligible for recovery without participating in the case [4]. Group 3: Company Background - Robbins LLP is a law firm specializing in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against SelectQuote, Inc. concerning allegations of securities fraud and unlawful business practices [1][2] Group 1: Lawsuit Details - The class action lawsuit involves claims that SelectQuote and its officers engaged in securities fraud or other unlawful business practices [2] - Investors have until October 10, 2025, to request to be appointed as Lead Plaintiff if they purchased SelectQuote securities during the Class Period [2] Group 2: Allegations by the DOJ - On May 1, 2025, the U.S. Department of Justice filed a False Claims Act complaint against SelectQuote, alleging the company received "tens of millions of dollars" in illegal kickbacks from health insurance companies from 2016 to at least 2021 [4] - The DOJ claims SelectQuote conspired with major insurers to discriminate against less profitable beneficiaries, including those with disabilities [4] - SelectQuote allegedly made materially false claims about offering "unbiased coverage comparisons," directing Medicare beneficiaries to plans that paid them the most money [4] - Following the DOJ's announcement, SelectQuote's stock price fell by $0.61 per share, or 19.24%, closing at $2.56 per share on May 1, 2025 [4]

Core Viewpoint - A class action lawsuit has been filed against SelectQuote, Inc. due to allegations of receiving illegal kickbacks from health insurance companies and misleading Medicare beneficiaries [1][3][4]. Group 1: Legal Allegations - The U.S. Department of Justice filed a complaint against SelectQuote, alleging that from 2016 to at least 2021, the company received "tens of millions of dollars" in illegal kickbacks for steering Medicare beneficiaries to specific insurance plans [3]. - The complaint claims that SelectQuote made materially false statements regarding its services, asserting it provided unbiased coverage comparisons while actually directing beneficiaries to the most profitable plans for the company [4]. - SelectQuote is accused of failing to disclose significant adverse facts about its business practices, including directing beneficiaries to plans based on compensation rather than quality [4]. Group 2: Financial Impact - Following the DOJ's announcement, SelectQuote's stock price dropped by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, with unusually high trading volume [3]. Group 3: Investor Actions - Investors who purchased SelectQuote securities between September 9, 2020, and May 1, 2025, are encouraged to contact Bragar Eagel & Squire for potential legal recourse [1][5]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 10, 2025 [1].

SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired SelectQuote, Inc. (NYSE: SLQT) securities between September 9, 2020 and May 1, 2025. SelectQuote is an insurance broker which sells Medicare Advantage and other health insurance plans online and by telephone. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP ...

Company Overview - Humana Inc. is a for-profit health insurance company that provides Medicare Advantage, individual and group insurance, pharmacy benefit management, and integrated care services through its CenterWell network [3] Allegations of Wrongdoing - The Department of Justice filed a False Claims Act complaint against Humana on May 1, 2025, alleging that from 2016 to at least 2021, the company paid illegal kickbacks to health insurance brokers for enrollments into its Medicare Advantage plans [4] Market Reaction - Following the announcement of the DOJ lawsuit, Humana's stock price fell by $6.20 per share, or 2.36%, closing at $256.04 per share on May 1, 2025 [5]

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Semler Scientific Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Disclosure - On February 28, 2025, Semler filed its annual report for 2024, indicating a risk of a complaint from the U.S. Department of Justice (DOJ) related to a civil False Claims Act lawsuit [3]. - Semler disclosed receiving an initial civil investigative demand from the DOJ in July 2017 concerning reimbursement claims for its QuantaFlo device [3]. - The company participated in unsuccessful settlement discussions with the DOJ in February 2025 [3]. Group 2: Market Reaction - Following the news of the DOJ investigation, Semler's stock price dropped by $4.03 per share, or 9.4%, closing at $38.89 per share on March 3, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving Humana Inc. following a lawsuit filed by the U.S. Department of Justice alleging illegal kickbacks related to Medicare Advantage plans [1][3]. Group 1: Investigation and Legal Actions - Pomerantz LLP is representing investors of Humana Inc. in an investigation concerning possible securities fraud or unlawful business practices by the company and its officers [1]. - The U.S. Department of Justice filed a False Claims Act complaint against Humana and other health insurance companies, alleging that from 2016 to 2021, they paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [3]. - Following the DOJ's lawsuit announcement, Humana's stock price decreased by $6.20 per share, or 2.36%, closing at $256.04 on May 1, 2025 [3]. Group 2: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in fighting for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - SelectQuote's stock price dropped over 19% following a lawsuit filed by the U.S. Department of Justice, alleging violations of the False Claims Act related to its business practices in the Medicare Advantage sector [1][3]. Company Investigation - Hagens Berman is investigating SelectQuote for potential misconduct regarding its sales practices and disclosures, particularly in its Senior business that offers Medicare Advantage plans [2][4]. - The investigation is focused on whether SelectQuote's claims of providing unbiased advice and comparison shopping for Medicare plans were misleading [3][4]. Allegations Against SelectQuote - The DOJ's complaint alleges that from 2016 to at least 2021, SelectQuote and other brokers received substantial payments from insurers for enrollments into Medicare Advantage plans, which may have influenced their sales practices [7]. - It is claimed that SelectQuote directed beneficiaries to plans that provided the highest kickbacks, rather than those that were most suitable for the beneficiaries [7]. - The company allegedly incentivized employees to prioritize plans based on kickbacks and discriminated against Medicare Advantage beneficiaries with disabilities [7].